keyword
https://read.qxmd.com/read/38412882/prophylactic-anticoagulation-to-prevent-left-ventricular-thrombus-following-acute-myocardial-infarction-a-systematic-review-and-meta-analysis
#21
JOURNAL ARTICLE
Ethan Sacoransky, Danny Yu Jia Ke, Bryce Alexander, Wael Abuzeid
Clinical practice guidelines from the American Heart Association recommend consideration of prophylactic anticoagulation to prevent left ventricular thrombus (LVT) formation in anterior ST-elevation myocardial infarction (STEMI) patients. These guidelines were given a low certainty of evidence (Class IIb, Level C), relying primarily on case studies and expert consensus to inform practice. Our objective was to compare the safety and efficacy of prophylactic anticoagulation, in addition to dual antiplatelet therapy (DAPT), in the current era of timely primary percutaneous coronary intervention (pPCI)...
February 25, 2024: American Journal of Cardiology
https://read.qxmd.com/read/38409912/perioperative-complications-of-arteriovenous-tirofiban-administration-versus-oral-dual-antiplatelet-therapy-for-stent-assisted-embolization-treated-aneurysmal-subarachnoid-hemorrhage-a-retrospective-controlled-cohort-analysis
#22
JOURNAL ARTICLE
Kaishan Wang, Yujie Chen, Yao Xu, Chen Yang, Zhaopan Lai, Binbin Tan, Gang Zhu, Hongping Miao
BACKGROUND: Major perioperative complications of stent-assisted embolization treated for aneurysmal subarachnoid hemorrhage patients include the formation of thromboembolic events (TEs) and hemorrhagic events (HEs), for which antiplatelet protocols play a key role. METHODS: We conducted a single-center retrospective analysis to compare the differences between arteriovenous tirofiban administration with traditional oral dual antiplatelet therapy (DAPT). A total of 417 consecutive patients were enrolled...
February 2024: Brain and Behavior
https://read.qxmd.com/read/38402925/prolonged-dual-antiplatelet-therapy-in-acute-myocardial-infarction-patients-without-revascularization-china-acute-myocardial-infarction-cami-registry-study
#23
JOURNAL ARTICLE
Cunrong Huang, Jingang Yang, Ling Li, Shenghu He, Xuxia Zhang, Haiyan Xu, Yuan Wu, Jun Zhang, Shubin Qiao, Yongjian Wu, Yanyan Zhao, Yang Wang, Wei Li, Chen Jin, Xiaojin Gao, Yuejin Yang
At least 12-month dual antiplatelet therapy (DAPT) is one of the standards of care following Percutaneous Coronary Intervention (PCI) in patients with acute coronary syndrome. However, study on prolonged DAPT for acute myocardial infarction (AMI) patients without revascularization is limited. We studied 1744 AMI patients without revascularization from the China Acute Myocardial Infarction registry between January 2013 and September 2014. These patients were on DAPT and did not experience AMI, stroke, or bleeding events at 12-month follow-up...
February 23, 2024: American Journal of Cardiology
https://read.qxmd.com/read/38396553/-notch1-as-a-negative-regulator-of-avian-adipocyte-differentiation-implications-for-fat-deposition
#24
JOURNAL ARTICLE
Zheng Wang, Yue Su, Mingyu Zhao, Zhenhua Ma, Jianhui Li, Zhuocheng Hou, Huifeng Li
The NOTCH signaling pathway plays a pivotal role in diverse developmental processes, including cell proliferation and differentiation. In this study, we investigated whether this signaling molecules also contribute to avian adipogenesis. Using previous mRNA-seq datasets, we examined the expression of 11 signaling members during avian adipocyte differentiation. We found most members are down-regulated throughout differentiation ( p < 0.05). As a representative, NOTCH1 was decreased in cultured chicken abdominal adipocytes during adipogenesis at mRNA and protein levels ( p < 0...
February 9, 2024: Animals: An Open Access Journal From MDPI
https://read.qxmd.com/read/38395748/stroke-and-high-risk-tias-outcomes-with-reduction-of-treatment-duration-when-treatment-initiated-in-emergency-rooms-shorter-study
#25
JOURNAL ARTICLE
Adel Alhazzani, Fahad AlAjlan, Ali Alkhathaami, Fahmi Mohammed Al-Senani, Taim Muayqil, Saeed Alghamdi, Ammar AlKawi, Saeed AlZahrani, Majid Bakheet, Mohammed Aljohani, Nouran Taher, Abdulkarim Almutairi, Mustafa AlQarni, Sadiq Alsalman, Saeed Alqahtani, Nouf Almansour, Laila Abukhamsin, Amr Mouminah, Nehal Bekheet AlModarra, Gamal Mohamed, Meshal Almodhy, Eid Ali Albogumi, Mohamed AlZawahmah, Abdulrahman AlReshaid, Naveed Akhtar, Muhammad Shazam Hussain, Gregory W Albers, Ashfaq Shuaib
BACKGROUND: Following TIA and minor stroke, the risk of recurrent stroke can be significantly reduced with short duration dual antiplatelet therapy (DAPT). We wish to investigate if 10 days of DAPT is as effective as 21 days treatment. STUDY DESIGN: This is an open-label, randomized, parallel-group study comparing whether 10 days of DAPT treatment (ASA+Clopidogrel) is non-inferior to 21-day of DAPT. in patients with minor ischemic stroke (AIS) or high-risk transient ischemic attack (TIA)...
February 23, 2024: International Journal of Stroke: Official Journal of the International Stroke Society
https://read.qxmd.com/read/38392262/dual-antiplatelet-therapy-for-the-acute-management-and-long-term-secondary-prevention-of-ischemic-stroke-and-transient-ischemic-attack-an-updated-review
#26
REVIEW
Bernard P L Chan, Lily Y H Wong, Benjamin Y Q Tan, Leonard L L Yeo, Narayanaswamy Venketasubramanian
To improve the efficacy over antiplatelet monotherapy, dual antiplatelet therapy (DAPT) has been increasingly adopted in the management of non-cardioembolic stroke. For minor ischemic stroke and high-risk transient ischemic attack, the aspirin-clopidogrel combination is now recommended for acute short-term treatment, whereas aspirin-ticagrelor combination may be considered in selected patients, especially those with resistance to clopidogrel. For long-term stroke prevention, aspirin-dipyridamole combination has been used as an alternative to antiplatelet monotherapy, and aspirin or clopidogrel combined with cilostazole may be prescribed for added protection in high-risk patients...
January 31, 2024: Journal of Cardiovascular Development and Disease
https://read.qxmd.com/read/38392257/efficacy-and-safety-of-thirty-day-dual-antiplatelet-therapy-following-complex-percutaneous-coronary-intervention-a-systematic-review-and-meta-analysis
#27
REVIEW
Anastasios Apostolos, David-Dimitris Chlorogiannis, Grigorios Chrysostomidis, Maria Bozika, Filippos Timpilis, Angelos Kramvis, Grigoris V Karamasis, Georgios Leventopoulos, Periklis Davlouros, Grigorios Tsigkas
The optimal duration of DAPT after complex PCI remains under investigation. The purpose of this systematic review and meta-analysis was to explore the safety and efficacy of a one-month therapy period versus a longer duration of DAPT after complex PCI. We systematically screened three major databases, searching for randomized controlled trials or sub-analyses of them, which compared shortened DAPT (S-DAPT), namely, one month, and longer DAPT (L-DAPT), namely, more than three months. The primary endpoint was any Net Adverse Clinical Event (NACE), and the secondary was any MACE (Major Adverse Cardiac Event), its components (mortality, myocardial infarction, stroke, and stent thrombosis), and major bleeding events...
January 29, 2024: Journal of Cardiovascular Development and Disease
https://read.qxmd.com/read/38387095/immune-thrombocytopenic-purpura-and-intracranial-stenting
#28
JOURNAL ARTICLE
Sophia Pathan
Patients with immune thrombocytopenic purpura (ITP) presenting with indications for dual antiplatelet therapy (DAPT) can be difficult to manage due to the precarious balance of managing the need for increased platelet counts as well as inhibition of platelet activity. This case represents a 65 year old woman with ITP who presented with a bilateral subarachnoid hemorrhage secondary to a left ophthalmic aneurysm that required placement of a pipeline embolization device (PED) necessitating DAPT. After treatment of her ITP with pulse dexamethasone for four days, she was safely discharged on one month of DAPT with aspirin and ticagrelor then switched to aspirin monotherapy without any immediate complications...
February 22, 2024: Journal of Pharmacy Practice
https://read.qxmd.com/read/38384448/the-impact-of-patient-adherence-to-dual-antiplatelet-medication-following-percutaneous-coronary-intervention-on-the-occurrence-of-adverse-cardiovascular-events
#29
JOURNAL ARTICLE
J A Mansurova, Andrey Orekhov, A S Zhunuspekova, A A Kassymova, L K Karazhanova
BACKGROUND: The objective of this study is to examine the impact of medication adherence on the timing of non-cardiovascular serious events (NCDS) onset in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). METHODS: This prospective study was conducted at a single center and involved 220 ACS patients who underwent sequential PCI with stenting. The Morisky Green Levine Medication Adherence Scale was employed to assess adherence to dual antiplatelet therapy (DAPT) and its impact on NCDS occurrence...
2024: Patient Preference and Adherence
https://read.qxmd.com/read/38383477/importance-of-cerebral-angiography-in-the-evaluation-of-delayed-carotid-stent-thrombosis-a-case-report
#30
JOURNAL ARTICLE
Zaki Masoud, Juan Felipe Daza-Ovalle, Charles Esenwa
BACKGROUND: While noninvasive imaging is typically used during the initial assessment of carotid artery disease, digital subtraction angiography remains the gold standard for evaluating carotid stent thrombosis and stenosis (Krawisz in Cardiol Clin 39:539-549, 2021). This case highlights the importance of digital subtraction angiography for assessing carotid artery stent patency in place of non-invasive imaging. CASE PRESENTATION: We present a 61-year-old African American male patient with a history of right cervical internal carotid artery dissection that was treated with carotid artery stenting and endovascular thrombectomy, who developed recurrent right hemispheric infarcts related to delayed carotid stent thrombosis...
February 22, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38382856/monotherapy-with-p2y-12-inhibitors-after-dual-antiplatelet-therapy-filling-gaps-in-evidence
#31
JOURNAL ARTICLE
Giuseppe Andò, Luca Lombardo, Giulia Alagna, Antonino Micari, Bruno Francaviglia, Alessia Cascone, Piera Capranzano
BACKGROUND: Whether P2Y12 inhibitor monotherapy (P2Y12 -I) is superior to aspirin following DAPT discontinuation post-PCI remains to be established. METHODS: We updated our prior network meta-analysis where P2Y12 -I and aspirin had been compared with DAPT or directly with each other. The focus is specifically on the available direct evidence, now consisting of the three head-to-head comparisons of P2Y12 -I and aspirin in event-free PCI patients after DAPT. We include a Trial Sequential Analysis of the direct evidence based on meta-analytical literature...
February 19, 2024: International Journal of Cardiology
https://read.qxmd.com/read/38381102/-acute-coronary-syndrome-diagnosis-and-treatment
#32
JOURNAL ARTICLE
Julia Stehli, Barbara E Stähli
In Switzerland, about 20 000 people experience an acute coronary syndrome (ACS) event each year. Acute coronary syndromes comprise ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. The diagnosis is made based on the clinical presentation, a rise in cardiac biomarkers, and ischemic ECG changes. In patients with acute STEMI, urgent coronary angiography with primary percutaneous coronary intervention (PCI) to open the occluded artery is indicated...
January 2024: Praxis
https://read.qxmd.com/read/38379212/safety-and-efficacy-of-combined-dual-antiplatelet-therapy-and-factor-viii-prophylaxis-in-patients-with-haemophilia-a-after-acute-coronary-syndrome
#33
JOURNAL ARTICLE
Pasquale Agosti, Simona Maria Siboni, Alessandro Ciavarella, Sara Arcudi, Federico Boggio, Roberta Gualtierotti, Flora Peyvandi
INTRODUCTION: The increased life expectancy of patients with haemophilia A (HA) has led to a growing prevalence of cardiovascular risk factors and events. There is still scarce evidence on the safety and appropriate duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) in HA patients. AIM: We describe our experience on the clinical management of Italian HA patients after ACS. METHODS: Nine patients with congenital HA treated with DAPT after a revascularization procedure performed for ACS have been enrolled and followed at the Angelo Bianchi Bonomi Haemophilia and Thrombosis Center in Milan between 2005 and September 2022...
February 20, 2024: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://read.qxmd.com/read/38369974/ticagrelor-versus-adjusted-dose-prasugrel-in-acute-coronary-syndrome-with-percutaneous-coronary-intervention
#34
JOURNAL ARTICLE
Ming-Lung Tsai, Yuan Lin, Dong-Yi Chen, Ming-Shyan Lin, Chao-Yung Wang, I-Chang Hsieh, Ning-I Yang, Ming-Jui Hung, Tien-Hsing Chen
Dual antiplatelet therapy (DAPT) with ticagrelor or adjusted-dose prasugrel has been used for acute coronary syndrome (ACS). However, few studies have directly compared these two drugs. In this study, we compared the real-world applications and outcomes of these two drugs in patients with ACS who had undergone percutaneous coronary intervention (PCI). This retrospective cohort study was conducted using the data of eligible patients with ACS who had undergone PCI at Chang Gung Memorial Hospital System between June 2019 and December 2021...
February 19, 2024: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38346535/outcomes-of-antiplatelet-therapy-before-endovascular-treatment-of-acute-large-vessel-occlusion-data-from-the-angel-act-registry
#35
JOURNAL ARTICLE
Dapeng Sun, Shuo Li, Raynald, Xiaochuan Huo, Baixue Jia, Xu Tong, Anxin Wang, Ning Ma, Feng Gao, Dapeng Mo, Thanh N Nguyen, Zhongrong Miao
OBJECTIVES: To investigate whether single or dual antiplatelet therapy (SAPT or DAPT) within 24 hours before endovascular treatment (EVT) could improve the clinical outcomes of patients with large vessel occlusion (LVO). METHODS: Patients from the ANGEL-ACT registry were divided into antiplatelet therapy (APT) and non-APT groups. The APT group was divided into SAPT and DAPT groups. Outcome measurement included 90-day modified Rankin Scale (mRS) distribution, change in the NIHSS at 7 days or discharge, number of passes, modified first pass effect (mFPE), symptomatic intracranial hemorrhage (SICH), and mortality within 90 days...
February 10, 2024: Journal of Neuroradiology. Journal de Neuroradiologie
https://read.qxmd.com/read/38345058/discovery-of-anticancer-compound-possessing-potential-to-bind-%C3%AE-secretase-catalytic-subunit-and-inhibit-notch-promoter-activity
#36
JOURNAL ARTICLE
Atul Kumar Singh, Kumari Sunita Prajapati, Shashank Kumar
Gamma secretase (GS) is an important therapeutic target in anticancer drug discovery. Increased GS activity activates notch signaling pathway which is associated with cancer stemness and drug resistance in cancer cells. A total of 69,075 natural and their derivative compounds were screened to identify the lead compound on the basis of in silico GS catalytic domain binding potential and in vitro selective anticancer efficacy. STOCK1N-23234 showed higher dock score (-11.82) compared to DAPT (-9.2) in molecular docking experiment and formed hydrogen bond with the key amino acid (Asp385) involve in catalysis process...
February 12, 2024: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/38336211/stenting-for-traumatic-pseudoaneurysms-of-the-cervical-internal-carotid-artery-case-report-and-systematic-review
#37
JOURNAL ARTICLE
Andre A Payman, Nathan C Pecoraro, John T Tsiang, John Souter, Robert Hand, Carlos F Bechara, Joseph C Serrone
BACKGROUND: The optimal stenting approach for traumatic pseudoaneurysms (PSA) of the extracranial internal carotid artery (ICA) remains underinvestigated. We present a case of a traumatic pseudoaneurysm of the extracranial ICA managed with stenting and review of prior published similar cases. METHODS: The systematic review followed PRISMA-S guidelines and included studies that investigated traumatic pseudoaneurysms of the extracranial ICA managed by stent placement...
February 7, 2024: World Neurosurgery
https://read.qxmd.com/read/38335531/antithrombotic-stewardship-evaluation-of-platelet-reactivity-guided-cangrelor-dosing-using-the-verifynow%C3%A2-assay
#38
JOURNAL ARTICLE
Alexander Connery, Tania Ahuja, Alyson Katz, Serena Arnouk, Eric Zhu, John Papadopoulos, Sunil Rao, Cristian Merchan
Cangrelor may be used as a bridge when temporary interruption of dual antiplatelet therapy (DAPT) is necessary. However, the optimal dose and monitoring of cangrelor in patients remains unknown, especially in the setting of mechanical circulatory support (MCS). We conducted an observational, single-center, retrospective cohort study of patients that had PCI within 3 months and received cangrelor while admitted to any intensive care unit. The primary outcome was the incidence of any major adverse cardiovascular event (MACE)...
February 8, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38329476/beyond-traditional-pain-relief-a-review-of-alternative-analgesics-in-myocardial-infarction-patient-management
#39
REVIEW
Swarali Yatin Chodnekar, Nityanand Jain, Edouard Lansiaux, Deepkanwar Singh Panag, Valdis Gibietis
While morphine is the recommended first-line treatment for pain management in patients with acute coronary syndrome, recent studies have raised concerns about its association with adverse outcomes. Morphine has been found to cause delayed antiplatelet effects, decreased ticagrelor absorption, increased platelet reactivity, and compromised efficacy of dual antiplatelet therapy (DAPT). Alternative analgesics, such as lidocaine, fentanyl, and acetaminophen, have begun to emerge as viable alternatives, each with unique mechanisms and potential benefits...
February 8, 2024: Journal of Pain & Palliative Care Pharmacotherapy
https://read.qxmd.com/read/38326641/effect-of-ticagrelor-versus-clopidogrel-on-all-cause-and-cardiovascular-mortality-in-acute-coronary-syndrome-patients-with-hyperuricemia
#40
JOURNAL ARTICLE
Shanshan Nie, Yuhang Zhao, Zeying Feng, Chan Zou, Fangfang Ding, Liying Gong, Hongwei Lu, Yu Cao, Guoping Yang
BACKGROUND AND OBJECTIVE: The relationship between hyperuricemia and mortality in patients with acute coronary syndrome (ACS) is considerably controversial. Additionally, the strategy of dual antiplatelet therapy (DAPT) has not been evaluated in patients with ACS with hyperuricemia. This study aims to evaluate the impact of hyperuricemia on the prognosis of ACS and explore the efficacy of ticagrelor compared with clopidogrel in patients with hyperuricemia. METHODS: The study enrolled 4319 patients divided into hyperuricemia (HUA, n = 1060) and normouricemia (NUA, n = 3259) groups...
February 7, 2024: Clinical Drug Investigation
keyword
keyword
18118
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.